Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8939852 | 0.82 | CYP2D6 (0.42) | TSHRCYP2D6CYP2C19HIF1ASLC13A5 | |
| SCHEMBL30483393 | 0.75 | TSHR (0.33) | TSHRCYP2D6CYP2C19HIF1ASLC13A5 | |
| SCHEMBL13418129 | 0.69 | ALDH1A1 (0.33) | THRBTSHRALDH1A1 | |
| SCHEMBL25905083 | 0.69 | THRB (0.36) | THRBTSHRALDH1A1 | |
| SCHEMBL11026684 | 0.69 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL6384935 | 0.68 | ALDH1A1 (0.41) | THRBALDH1A1 | |
| SCHEMBL6245698 | 0.68 | CYP2D6 (0.37) | THRBTSHRCYP2D6CYP2C19HIF1A | |
| SCHEMBL28243170 | 0.67 | CYP2C19 (0.44) | TSHRCYP2D6CYP2C19HIF1AALDH1A1 | |
| SCHEMBL4329618 | 0.66 | CYP2D6 (0.42) | TSHRCYP2D6CYP2C19HIF1ASLC13A5 | |
| SCHEMBL10951922 | 0.66 | LMNA (0.33) | THRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117013-A1 | Aqueous Curable Multi-Component System | OMNITECHNIK MIKROVERKAPSELUNGS GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| EP-4460542-B1 | AQUEOUS CURABLE MULTI-COMPONENT SYSTEM | OMNITECHNIK MIKROVERKAPSELUNGS GMBH (DE) | 2025-07-16 | — | — | EP | disclosed |
| CN-111856877-A | Photosensitive resin composition, spacer, protective film and liquid crystal display element | 奇美实业股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117013-A1 | Aqueous Curable Multi-Component System | ITK, MAFK, BRSK1 | THRB 1685/4885TSHR 3882/4885CYP2D6 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.